Search clinical trials for: Temsirolimus, Rituximab, Bendamustin

Total 3516 results

Sandoz
Novartis Pharmaceuticals

Completed

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Rheumatoid Arthritis

United States, Spain, Turkey, Argentina, Austria, Belgium, Brazil, Estonia, France, Germany, Hungary, India, Italy, Romania
Centre Antoine Lacassagne
Millennium: The Takeda Oncology Company

Completed

Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient (HALO)

Safety | Clinical Efficacy

France
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer (MBC-6)

Breast Cancer

Austria
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Australia, Brazil, Canada, Mexico, New Zealand, Peru
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | CCND1 Positive | CCND2 Positive | CCND3 Positive | CD20 Positive | Refractory Mantle Cell Lymphoma

United States
Fondazione Italiana Linfomi ONLUS

Terminated

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting (FIL-BBV)

Lymphatic Diseases

Italy
Loyola University
Celgene

Terminated

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma (BVRD)

Multiple Myeloma

United States
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Lymphoma, B-Cell

Japan
Second Affiliated Hospital, School of Medicine,...

Recruiting

Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus

Autoimmune Diseases

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
Georgetown University
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer

Advanced Solid Tumors

United States
University Hospital Heidelberg
German Cancer Research Center; Janssen-Cilag International NV; inVentiv Health... and other collaborators

Completed

Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma (BPV)

Multiple Myeloma

Germany
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

B Cell Lymphoma

China
University of Wisconsin, Madison
Genentech, Inc.

Terminated

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Non-hodgkin Lymphoma

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Refractory Lymphoma | DLBCL | MYD88 Gene Mutation | Relapse | CD79A Gene Mutation | CD79B Gene Mutation
The Lymphoma Academic Research Organisation
Roche Pharma AG

Completed

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) (FLIRT)

Follicular Lymphoma

France
Assistance Publique - Hôpitaux de Paris

Completed

Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (MAINRITSAN 2)

Microscopic Polyangiitis | Granulomatosis With Polyangiitis | Renal Limited Forms

France
Genentech, Inc.
Roche Pharma AG

Completed

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

Non-Hodgkin's Lymphoma

United States, Spain, France, Canada, United Kingdom, Austria, Belgium, Czechia, Russian Federation, Italy, Switzerland, Germany, Netherlands, Sweden
Munich Municipal Hospital
German CLL Study Group

Unknown

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Chronic Lymphocytic Leucemia

Germany
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Indolent Adult Non-Hodgkin... and other conditions

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen, LP

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

CD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditions

United States
mAbxience Research S.L.
Laboratorio Elea Phoenix S.A.; Libbs Farmacêutica LTDA; Innogene Kalbiotech Pte... and other collaborators

Completed

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

Diffuse Large B-cell Lymphoma

Malaysia, Argentina, Colombia, India, South Africa, Philippines, Brazil, Russian Federation, Indonesia, Iran, Islamic Republic of, Mexico, Paraguay
Kuopio University Hospital

Completed

Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital (KuoRituxi1)

Rheumatoid Arthritis

Finland
Amgen

Completed

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Arthritis, Rheumatoid

United States, Germany, Bulgaria, Hungary, Poland, Estonia
Cairo University

Recruiting

Anti-Plaque and Anti-Gingivitis Effects of Moringa Plant Extract and Fluoride Toothpastes

Oral Disease

Egypt
Chinese PLA General Hospital

Recruiting

Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
UNC Lineberger Comprehensive Cancer Center

No longer available

Compassionate Use Re-Infusion of ATLCAR.CD30

Hodgkin Lymphoma, Adult

United States
Stanford University
Kyverna Therapeutics

Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive

United States
Incyte Corporation

Completed

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Lymphoma

Spain, Hungary, United States, Denmark, Italy, Czechia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma | CD20 Positive | T-Cell Non-Hodgkin Lymphoma

United States
Jeffrey W. Clark, MD
Wyeth is now a wholly owned subsidiary of Pfizer; Dana-Farber Cancer Institute and other collaborators

Completed

Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer

Colorectal Cancer | Colorectal Adenocarcinoma

United States
Narendranath Epperla
Eli Lilly and Company

Not yet recruiting

Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma

Marginal Zone Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
German CLL Study Group
Gilead Sciences; Hoffmann-La Roche

Completed

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

Chronic Lymphocytic Leucemia

Germany
Genentech, Inc.

Completed

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Goethe University

Completed

Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia (TOR-AML)

Acute Myeloblastic Leukemia

Germany
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; SWOG Cancer Research...

Completed

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
Seagen Inc.

Completed

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Hodgkin Disease

United States
University of Washington
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal...

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Hodgkin Lymphoma

China
German CLL Study Group
AbbVie; Hoffmann-La Roche

Active, not recruiting

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Chronic Lymphocytic Leucemia

Germany
The Lymphoma Academic Research Organisation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea; Swiss Group... and other collaborators

Recruiting

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (MorningLyte)

Follicular Lymphoma

Belgium, France, Germany, Portugal, Spain
University Hospital Inselspital, Berne
Mundipharma Medical Company

Completed

Bendamustine and Melphalan in Myeloma (BEB-2)

Multiple Myeloma

Switzerland
Weill Medical College of Cornell University

Completed

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States

Search clinical trials for: Temsirolimus, Rituximab, Bendamustin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations